Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



1248 Features
eHealth News Roundup for 10th - 21st February, 200

26 Feb 03

The growing number of ePrescribing, health information and other technological initiatives mean that IT is becoming an ever more important and integral part of the healthcare system, for doctors and p
Michael Randle

Anticonvulsants: Pfizer's pregabalin to top succes

26 Feb 03

Ever since it first came to market in 1993, the anticonvulsant drug Neurontin has consistently been one of Pfizer's top earners, generating considerable sales and driving strong growth for the New Yor
Michael Randle

Drug Development: Time and Money

20 Feb 03

The pharmaceutical industry’s expectations for increasing revenue rely to a large extent on ensuring that their heavy R&D investment translates into new drugs. In 2000, the global pharmaceutical indu
Pietro Bonacossa

Multiple Myeloma: Increasing the therapeutic optio

20 Feb 03

High-dose therapy for multiple myeloma is effective in increasing median survival, but is severely toxic, limiting its use. In addition, all patients eventually relapse and suffer disease progression.
Michael Randle

Dinosaurs, Drugs and Politics

19 Feb 03

The pharmaceutical industry, much of which dreams of having the marketing agility of a primitive vertebrate, has found a sales-promotion tool that sometimes works in the United States and New Zealand.
Mark Chataway

Opportunities for the treatment of cancer, stroke

14 Feb 03

It is now well established that cellular suicide (apoptosis or programmed cell death) is central to a number of physiological cellular processes and is essential in the maintenance of homeostasis and
Dr Jon Goldhill

eHealth News Roundup for January 27th - February 7

11 Feb 03

The past fortnight saw a number of eHealth developments. Patients and consumer groups were particularly well catered for with the launch of important new cancer, diabetes, back pain, STD, substance ab
Michael Randle

Recruitment for Medical Jobs within the Pharmaceut

07 Feb 03

The pharmaceutical industry has a wide range of roles for medics, from clinical pharmacology where the clinical care of study subjects is your responsibility, to the position of medical adviser, which
Sue Ransom

Making a Success of R&D Partnerships

04 Feb 03

Biopharmaceutical companies face numerous challenges to boost their output of new chemical entities and to strengthen their product pipelines. In order to remain profitable and competitive, they have
Pietro Bonacossa

Driving Patient Compliance

03 Feb 03

Non-compliance is the failure of patients to take medicines in their prescribed manner. Patient non-compliance is a serious healthcare issue, with studies showing that it can range from 20% to 80% dep
Pietro Bonacossa

Hormonal Cancers: Key drivers in a market of chang

03 Feb 03

Four major brands, TAP’s Lupron, AstraZeneca’s Zoladex, Nolvadex and Casodex, account for 49% of the total value of the anti-hormonals market at present. The loss of patent protection for these compou
Michael Randle

eHealth News Roundup for 13th - 24th January 2003 from Datamonitor

03 Feb 03

Over the past fortnight the Internet has benefited from Healthcare initiatives with a number of online health information tools being launched in particular. Schering-Plough led the way on this front but the leading pharmaceuticals were not all so happy. GlaxoSmithKline, for example, recently received criticism over its threat to stop supplying drugs to Canadian online pharmacies. These stories and others are covered in detail in this week’s eHealth News Roundup.
Michael Randle

Lung Cancer: Eli Lilly’s Affinitac to challenge th

03 Feb 03

Lung cancer is one of the most prevalent forms of cancer to afflict both men and women, accounting for nearly 15% of all cancer cases. The size of the lung cancer market - estimated at $1.6bn in 2002
Michael Randle

TherapeuticAdvances: 23rd January 2003

03 Feb 03

The current edition of TherapeuticAdvances features data on the targeting of ion channels and TNF-alpha for treatment of inflammation; stem cell approaches to cardiovascular angiogenesis; improved pro
Dr Jon Goldhill

What’s your Drug Development Really Worth?

30 Jan 03

Drug development is an expensive and risk-intensive process. Even if a company manages to get its products to market, success is not guaranteed as there is the threat of competitors to contend with.
Dr Faiz Kermani

Diabetes: time for a new regime?

22 Jan 03

In 2001, diabetes drugs represented six of the leading 100 pharmaceutical brands in terms of global sales, combining for $8.2 billion in sales. Sales were led by Bristol-Myers Squibb's Glucophage fran
Michael Randle

Therapeutic Advances: 10th January 2003

15 Jan 03

The current edition of TherapeuticAdvances features data on anti-migraine drugs; emerging approaches to the blockade of transcription, angiogenesis and metastasis; and two therapeutic strategies for t
Dr Jon Goldhill

The Best in Class?

15 Jan 03

Is GSK a thrusting new pharma co or an ageing dinosaur? Pfast Forward went to the UK HQ to find out.

Smallpox vaccines: to invest or not to invest, tha

13 Jan 03

During the last year bioterrorism has attracted a high level of media and clinical attention. However, this publicity does not necessarily reflect a potential opportunity for easy market entry or high
Michael Randle

National Health Service: handling heart failure

17 Dec 02

The number of people with chronic heart failure in the western world is increasing so rapidly that, according to Datamonitor's EpiVision forecasts, by 2015 there will be 1.5 million sufferers in the UK alone. Although this is small in comparison to the 8.2 million already suffering from the condition in the US, the problem is great enough to represent a real danger for the already beleaguered NHS.
Johan Short

Medical Devices and Clinical Trials: Exploring a N

13 Dec 02

As the medical device field becomes more advanced the need for clinical trials will grow. With less experience of global clinical trials than those in the pharmaceutical sector, medical device compani
Dr Faiz Kermani and Jeff Kingston

Man or Mouse?

10 Dec 02

The scientific community seemed to move into overdrive with the publication of the human genome, and the popular media responded this with reports of rapid advances to come in the field of human medic
Paul Hartigan

Big pharma: tightening the marketers' purse strings

06 Dec 02

According to new research pharmaceutical companies are investing more than ever to promote their drugs. Growth in promotional investment is thought to be increasing at a faster rate than growth in ethical sales. With this trend unlikely to continue because of economic constraint can the drug companies increase the impact of their marketing or do they face the prospect of slashing expenditure?
Michael Randle

eHealth News Roundup for 18th - 29th November 2002

03 Dec 02

The healthcare industry is increasingly looking to take advantage of the Internet and one of the leading pharmaceutical groups is leading the way. Schering-Plough has recognized the potential benefit
Johan Short

Cancer: Iressa prepares for a rush of blood

03 Dec 02

Despite significant initial interest in angiogenesis inhibitors, they have failed to live up to expectations and are yet to be approved by the FDA for cancer treatment. However, there are a number of
Johan Short

Patient Recruitment: The New Challenge in Clinical Research

22 Nov 02

Patient enrollment is of continued interest, as many companies believe it is possible to improve clinical cycle times by compressing the enrolment period. However, this means recognizing the fact that the nature of the trial will affect the recruitment period and so the degree of improvement that can be made will differ from trial to trial.
Pietro Bonacossa and Faiz Kermani

Senior Executive Recruitment

20 Nov 02

Lets have a look at the healthcare market and some of the things that are changing within it and then assess the impact of the changes on companies’ ability to achieve effective recruitment.
Peter Fortune

TherapeuticAdvances: 14th November, 2002

20 Nov 02

This week’s TherapeuticAdvances focuses on histone deacetylase inhibitors; in particular their use as antifungal as well as anti-metastatic agents. We also feature compelling data supporting the use o
Jon Goldhill

QP or not QP – a career worth considering

15 Nov 02

Demand for QPs has increased dramatically in the last 10-15 years as a result of an aging demographic in this role.
Jeff Webb - PIR Group

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.